Testicular seminoma stage I: Treatment results and long-term follow-up (1968-1988)

M. E. Stein, I. Kessel, N. Luberant, A. Kuten

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Sixty-nine patients with stage I testicular seminoma were referred to the Northern Israel Oncology Center between 1968 and 1987. Sixty-four patients were irradiated postoperatively and five patients had surveillance alone. Complete follow-up was available for all patients, with a median follow-up of 86 months (range 9-239 months). The last follow-up was in December 1988. Actuarial survival was 94% to 5, 10, 15, and 20 years. Six patients relapsed following completion of irradiation. All the recurrences occurred outside the radiation field. Three of the relapsed patients could be salvaged with cisplatinum-based chemotherapy and are alive at 4, 7, and 10 years following second-line treatment. Acute or chronic side effects were mild and manageable. Seven patients developed second primary cancers, two within and six outside the radiation field. While surveillance policy alone in stage I testicular seminoma may be successful in terms of patient outcome, it requires prolonged observation, good compliance of patients, and intensive use of resources. Thus, until proved otherwise, infradiaphragmatic radiotherapy should further remain the optimal routine treatment in seminoma patients with stage I disease.

Original languageEnglish (US)
Pages (from-to)175-179
Number of pages5
JournalJournal of Surgical Oncology
Volume53
Issue number3
StatePublished - 1993
Externally publishedYes

Fingerprint

Seminoma
Therapeutics
Radiation
Second Primary Neoplasms
Israel
Patient Compliance
Radiotherapy
Observation
Recurrence
Drug Therapy
Survival

Keywords

  • good prognosis
  • radiotherapy
  • stage I seminoma

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Stein, M. E., Kessel, I., Luberant, N., & Kuten, A. (1993). Testicular seminoma stage I: Treatment results and long-term follow-up (1968-1988). Journal of Surgical Oncology, 53(3), 175-179.

Testicular seminoma stage I : Treatment results and long-term follow-up (1968-1988). / Stein, M. E.; Kessel, I.; Luberant, N.; Kuten, A.

In: Journal of Surgical Oncology, Vol. 53, No. 3, 1993, p. 175-179.

Research output: Contribution to journalArticle

Stein, ME, Kessel, I, Luberant, N & Kuten, A 1993, 'Testicular seminoma stage I: Treatment results and long-term follow-up (1968-1988)', Journal of Surgical Oncology, vol. 53, no. 3, pp. 175-179.
Stein, M. E. ; Kessel, I. ; Luberant, N. ; Kuten, A. / Testicular seminoma stage I : Treatment results and long-term follow-up (1968-1988). In: Journal of Surgical Oncology. 1993 ; Vol. 53, No. 3. pp. 175-179.
@article{53314b3d3f644487a39a9fb06c9fd1a4,
title = "Testicular seminoma stage I: Treatment results and long-term follow-up (1968-1988)",
abstract = "Sixty-nine patients with stage I testicular seminoma were referred to the Northern Israel Oncology Center between 1968 and 1987. Sixty-four patients were irradiated postoperatively and five patients had surveillance alone. Complete follow-up was available for all patients, with a median follow-up of 86 months (range 9-239 months). The last follow-up was in December 1988. Actuarial survival was 94{\%} to 5, 10, 15, and 20 years. Six patients relapsed following completion of irradiation. All the recurrences occurred outside the radiation field. Three of the relapsed patients could be salvaged with cisplatinum-based chemotherapy and are alive at 4, 7, and 10 years following second-line treatment. Acute or chronic side effects were mild and manageable. Seven patients developed second primary cancers, two within and six outside the radiation field. While surveillance policy alone in stage I testicular seminoma may be successful in terms of patient outcome, it requires prolonged observation, good compliance of patients, and intensive use of resources. Thus, until proved otherwise, infradiaphragmatic radiotherapy should further remain the optimal routine treatment in seminoma patients with stage I disease.",
keywords = "good prognosis, radiotherapy, stage I seminoma",
author = "Stein, {M. E.} and I. Kessel and N. Luberant and A. Kuten",
year = "1993",
language = "English (US)",
volume = "53",
pages = "175--179",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Testicular seminoma stage I

T2 - Treatment results and long-term follow-up (1968-1988)

AU - Stein, M. E.

AU - Kessel, I.

AU - Luberant, N.

AU - Kuten, A.

PY - 1993

Y1 - 1993

N2 - Sixty-nine patients with stage I testicular seminoma were referred to the Northern Israel Oncology Center between 1968 and 1987. Sixty-four patients were irradiated postoperatively and five patients had surveillance alone. Complete follow-up was available for all patients, with a median follow-up of 86 months (range 9-239 months). The last follow-up was in December 1988. Actuarial survival was 94% to 5, 10, 15, and 20 years. Six patients relapsed following completion of irradiation. All the recurrences occurred outside the radiation field. Three of the relapsed patients could be salvaged with cisplatinum-based chemotherapy and are alive at 4, 7, and 10 years following second-line treatment. Acute or chronic side effects were mild and manageable. Seven patients developed second primary cancers, two within and six outside the radiation field. While surveillance policy alone in stage I testicular seminoma may be successful in terms of patient outcome, it requires prolonged observation, good compliance of patients, and intensive use of resources. Thus, until proved otherwise, infradiaphragmatic radiotherapy should further remain the optimal routine treatment in seminoma patients with stage I disease.

AB - Sixty-nine patients with stage I testicular seminoma were referred to the Northern Israel Oncology Center between 1968 and 1987. Sixty-four patients were irradiated postoperatively and five patients had surveillance alone. Complete follow-up was available for all patients, with a median follow-up of 86 months (range 9-239 months). The last follow-up was in December 1988. Actuarial survival was 94% to 5, 10, 15, and 20 years. Six patients relapsed following completion of irradiation. All the recurrences occurred outside the radiation field. Three of the relapsed patients could be salvaged with cisplatinum-based chemotherapy and are alive at 4, 7, and 10 years following second-line treatment. Acute or chronic side effects were mild and manageable. Seven patients developed second primary cancers, two within and six outside the radiation field. While surveillance policy alone in stage I testicular seminoma may be successful in terms of patient outcome, it requires prolonged observation, good compliance of patients, and intensive use of resources. Thus, until proved otherwise, infradiaphragmatic radiotherapy should further remain the optimal routine treatment in seminoma patients with stage I disease.

KW - good prognosis

KW - radiotherapy

KW - stage I seminoma

UR - http://www.scopus.com/inward/record.url?scp=0027217201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027217201&partnerID=8YFLogxK

M3 - Article

C2 - 8331939

AN - SCOPUS:0027217201

VL - 53

SP - 175

EP - 179

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -